Immunomic Therapeutics

The platform’s defining moment came in October 2015, when Immunomic signed a worldwide licensing agreement with Astellas Pharma covering LAMP-vax products for allergic disease — a deal reported at $300 million in upfront and milestone payments plus double-digit royalties, while Immunomic retained the rights to apply the LAMP platform to other indications including cancer immunotherapy.

The momentum continued well beyond the Astellas deal: years later Immunomic closed a $61.3 million financing round led by the Korean investment group HLB Co., Ltd. — well above its original $50 million target — to fund clinical development of ITI-1000 and expand manufacturing capacity roughly tenfold. That later, much larger institutional round is itself a signal of the impact of the earlier angel capital: it was Keiretsu Forum-era funding that kept the LAMP platform alive long enough to reach the licensing deal that made Immunomic credible to large-scale institutional biotech investors afterwards.

Two notes on how this relationship is reported. First, LAMP-vax is not a separate company: it is Immunomic’s own core vaccine platform, and the “$300M Astellas licensing deal” sometimes listed against it is the identical October 2015 transaction described here. Keiretsu Forum appears to track the relationship as two line items, plausibly because different chapters or different rounds each report their own investment amount and return multiple against the same eventual outcome — a $3.2 million investment returning 4.4x and a separately reported 45x on Immunomic overall are not contradictory, since later investors buy in at a higher valuation and see a smaller multiple on the same event. Second, while the $300M Astellas deal is well documented in the trade press, the 45x figure is not independently verifiable, and the same multiple appears in a Keiretsu Forum article describing the Telltale Games exit — worth reconciling against the original source materials.